USFDA concludes inspection at Zydus Lifesciences Ahmedabad site with zero observations
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-02-18 09:00 GMT | Update On 2025-02-18 09:00 GMT
SMS Pharma successfully completes USFDA inspection at Telangana Central Laboratory Analytical Services
Advertisement
Ahmedabad: Zydus Lifesciences has informed in a BSE filing that the US Food and Drug Administration (USFDA) has concluded a routine surveillance inspection with NIL observations at the group’s Topical Manufacturing site situated at Changodar in Ahmedabad.
The inspection was conducted from February 10th to 14th, 2025.
Medical Dialogues team had earlier reported that the Company had successfully completed a USFDA surveillance inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Ambernath, Maharashtra.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.